

***Remarks***

The disclosure has been amended at page 12 to correct the typographical error at line 7, “between 15 and 24 molecules”. Support for this should be recognized by the skilled artisan, as well as by page 12 starting with line 5; and at page 34, lines 1-4.

Claims 4-6, 9-11, 24, 26, and 35 to 48 are now pending in the application, with claims 4, 6 and 24 being the independent claims. Claim 6 has been amended, and claims 43 to 48 are newly presented. The instant amendments are believed to introduce no new matter.

Support for the amendments to the claims can be found throughout the specification as well as in the claims as originally filed. More specifically, we direct the Examiner’s attention to page 12 of the disclosure. Indeed page 12, line 6, gives literal support for “at least 12 nucleotides”. More specific support for new claim 43 can be found at page 12, line 6; at page 34, lines 1-4; as well as in claim 6, as originally filed. More specific support for claim 44 may be found at page 12, line 7. Support for new claims 47 and 48 can be found, for example, starting at page 44, line 26, to page 45, line 3, as well as page 45 between lines 19-23.

Applicants thank the Examiner for the withdrawal of the rejection of claims 4, 5, 10, 11, 24, 35 and 36 under 35 U.S.C. § 112, first paragraph, for failing to comply with the written description requirement.

Applicants also thank the Examiner for the withdrawal of the rejection of claims 6 and 9 under 35 U.S.C. § 102 as being anticipated by U.S. Patent No. 6,528,260 of Blumfeld.

Applicants further thank the Examiner for the telephone interview of January 9, 2007.

***Rejections Under 35 U.S.C. § 112, first paragraph***

The rejection of claims 6 and 9 under 35 U.S.C. § 112, first paragraph, as failing to comply with the written description requirement is respectfully traversed.

The Examiner is of the opinion that the recitation “11” in claim 6 “was not described in a such a way as to reasonably convey to one skilled artisan in the relevant art that the inventor(s), at the time the application was filed, had possession of the claimed invention. The Examiner further alleges that page 34 “does not have support for “11”. Applicants respectfully disagree. In accordance to U.S. practice and jurisprudence, literal support is not a requirement *per se*. Applicants respectfully submit that the recitation “at least 10 consecutive nucleotides” comprises “at least 11”, “at least 12,” etc. Applicants respectfully submit that the skilled artisan cognizant of the present invention and the state of the art would find “at least 11” to be fully supported by the application.

Nevertheless, in order to bring this case in condition for allowance, Applicants have replaced “11” by “12”, a recitation which finds literal support in the application as filed. This amendment is carried out without prejudice or disclaimer. Applicants reserve the right to prosecute the “at least 11” or “from 11 to 50” language in further applications.

Accordingly, reconsideration and withdrawal of the rejection of claims 6 and 9 under 35 U.S.C. § 112, first paragraph, is respectfully requested.

**Conclusion**

Prompt and favorable consideration of this Amendment is respectfully requested. Applicants believe the present application is in condition for allowance. If the Examiner believes, for any reason, that personal communication will expedite prosecution of this application, the Examiner is invited to telephone the undersigned at the number provided.

Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.



Cynthia M. Bouchez  
Attorney for Applicants  
Registration No. 47,438

Date: Feb. 16, 2007  
1100 New York Avenue, N.W.  
Washington, D.C. 20005-3934  
(202) 371-2600